注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

zliming2004的博客

新药研发与药物合成

 
 
 

日志

 
 
 
 

罗氏抗癌新药Idasanutlin(RG7388)  

2015-07-12 20:25:01|  分类: 药物化学 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

罗氏抗癌新药Idasanutlin(RG7388)的化学结构 Chemical Structure of Roche’s Anticancer Agent Idasanutlin(RG-7388)

RG7388 (Idasanutlin) is the second generation inhibitor of p53-MDM2 interaction.It is orally active, potently and selectively antagonizing the p53-MDM2 interaction with Ki at low nM. Highly optimized from pyrrolidin-based derivatives, RG7388 represents a distinctive, brand-new structural category of MDM2 ligand, a significant departure from the nutlin-based, first generation ligands exemplified by RG7112. Like RG7112, RG7388 binds selectively to the p53 site on the surface of the MDM2 molecule, effectively displacing p53 from MDM2, leading to p53 stabilization and activation of the p53 pathway. However, RG7388, as compared with its predecessor, binds to the MDM2 protein with a higher potency and selectivity, and has substantially improved pharmacological properties and superior clinical efficacy at lower doses and exposures.

Chemical Structure of Idasanutlin_RG-7388_Antineoplastic_Roche

Generic Name:Idasanutlin
Synonym:RG-7388, RG7388, RO5503781
CAS Number:1229705-06-9
Chemical Name:4-[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxamido]-3-methoxybenzoic acid
Mechanism of Action:p53-MDM2 Inhibitor
Indication:Prostate cancer,Acute myeloid leukaemia, Essential thrombocythaemia; Polycythaemia vera
Originator:Roche
Developer:Roche,NHS Greater Glasgow and Clyde; University of Glasgow

 Phase Organization Condition
Phase IRocheCancer, solid tumor
Phase IRocheLeukemia, acute myeloid
Phase IRochePolycythemia vera
Phase IRocheThrombocythemia, essential

RG-7388 is an MDM2 (hdm2) inhibitor in early clinical trials at Roche for the oral treatment of solid tumors, acute myeloid leukemia, essential thrombocythemia and polycythemia vera.


In 2014, orphan drug designation was assigned in the E.U. for the treatment of acute myeloid leukemia.

罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客

 

罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客

 罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客

 
罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客
 

Patent NumberApplicantTitleConditionSubject MatterWO 2014128094
 F. Hoffmann-La Roche AG  Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客  

Cancer

罗氏抗癌新药Idasanutlin(RG7388) - zliming2004 - zliming2004的博客  Synthesis
 

来源:

1.Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10:431-442. PMID: 12719720
2.Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899-2908. PMID: 15838523
3.Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23-31. PMID: 17126603
4.Melnikova VO, Ananthaswamy HN. Chapter 8: P53 protein and non-melanoma skin cancer. In: Reichrath J, ed. Molecular Mechanisms of Basal Cell and Squamous Cell Carcinomas. Georgetown, TX: Landes Bioscience/Eurekah.com; 2006:66-72.
5.Vu BT, Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol. 2011;348:151-172. PMID: 21046355
6.Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453-3459. PMID: 9671804
7.Tan BX, Khoo KH, Lim TM, Lane DP. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Oncotarget. 2014;5:933-943. PMID: 24659749
8.Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979-5983. PMID: 23808545

This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

  评论这张
 
阅读(57)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017